

Zoono Group Limited (ASX: ZNO)**ASX ANNOUNCEMENT**15th March 2019**Zoono Signs Agreement with Midas Pharma GmbH**

Global biotech company Zoono Group Limited (ASX:ZNO) ('Zoono' or 'the Company') is pleased to announce that it has today signed an agreement in Ingelheim, Germany with Midas Pharma GmbH for sales and distribution in the EU and selected global markets. This agreement is the culmination of six months' work on behalf of both parties.

Midas is a highly regarded and respected global pharmaceutical partner company with sales and distribution channels across the global pharmaceutical and healthcare sectors. Zoono's agreement with Midas is an important step forward in its ambition to develop a global B2B business. The Zoono Board is confident that, with time and the other opportunities now available to Zoono in international markets, its global B2B business can become a significant contributor to the overall financial performance of Zoono in coming years.

For further information, please contact:**Zoono Group Limited****Paul Hyslop**

Managing Director/CEO

M: +64 21 659 977

E: paul.hyslop@zoono.com

Media & Investor Enquiries**Julia Maguire**

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

About Midas

Midas Pharma is an independent, family-owned company with its headquarters in Ingelheim Germany. Founded by Karl-Heinz Schleicher, Midas has over 200 staff in 10 countries. It has strategic reach and influence in the pharmaceutical and healthcare sectors, with a proven track record and excellent relationships with many generic, 'big pharma' and biotech companies. Midas has established strategic alliances to

complement its strengths and unique worldwide network of customers and suppliers in all major pharmaceutical markets.

Midas Pharma is well placed to present the Zoono technology at a strategic level in Europe and elsewhere around the world. Zoono expects its partnership with Midas will provide new opportunities for channel partners and distributors within key markets that are challenging to penetrate. Zoono looks forward to a mutually beneficial and strong working relationship with Midas moving forward.



Left to Right: Ellen Engel (Midas International Licencing Director), Anne Jarniou Klermund (Zoono Business Development Manager Europe), Paul Hyslop (Zoono Founder and CEO), Dirk Weidenbach (Midas Chief Operating Officer), Karl-Heinz Schleicher (Midas Founder and CEO), Florian Tetzner (Midas Sales and Marketing Director), James Milnes (Zoono Regional Manager UK and Europe)

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and

durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com